ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma
Shots:
- ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma
- ProMab Biotechnologies get an option to add five chimeric antigen receptor (CAR) targeting sequences based on natural killer (NK) cell therapies
- NantKwest’s lead NK cell platform includes haNK and taNK designed to induce cell death by innate- antibody-mediated- and CAR directed killing against cancer and virally induced infectious diseases
Ref: Nantkwest | Image: Nantkwest
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com